Healome Therapeutics Secures £2 Million Seed Funding for Innovative Eye-Drop Technology
Healome Therapeutics Secures £2 Million Seed Funding for Innovative Eye-Drop Technology
Healome Therapeutics, a promising spinout from the University of Birmingham, recently completed a significant funding round, raising £2 million in a seed round that was oversubscribed. The round was led by Empirical Ventures, with notable participation from DEBRA Research, Cure EB, Oshen Bio, and existing investor SFC Capital. This funding will accelerate the development of Healome's innovative eye-drop matrix technology designed to treat ocular surface diseases, enhancing the treatment landscape for millions affected by such conditions.
Understanding the Challenge of Ocular Surface Diseases
Ocular surface diseases are prevalent conditions affecting a large segment of the global population. One of the most recognized ailments in this field is dry eye syndrome, which currently impacts over 350 million individuals worldwide. The global market for dry eye treatment is valued at around $5 billion, reflecting a significant demand for effective solutions. However, traditional eye drops typically do not retain their effectiveness for long periods, often leading to frequent dosing of up to twenty times daily, which results in poor treatment adherence. Statistics indicate that only about 20% of patients comply with their prescribed dosing regimen for chronic conditions.
Healome's Innovative Solution
The core of Healome's approach lies in its proprietary eye-drop matrix technology. When applied, this novel matrix initially behaves like a liquid, facilitating easy application. It then restructures to form a protective, lubricating matrix that promotes drug retention on the ocular surface, addressing one of the critical shortcomings of conventional eye drops. This innovative platform has successfully demonstrated the capability to deliver various types of drugs, ranging from small molecules to complex biologics. In pre-clinical trials, it was shown to facilitate rapid corneal healing with minimal side effects when employed to administer an anti-scarring biologic.
The potential applications of this technology are extensive, aimed at conditions such as dry eye disease, inflammation of the ocular surface, corneal injuries, and along with rare diseases that lead to severe ocular surface damage. Healome has secured five patent families that fortify the intellectual property around its unique matrix structure, developed from safe pharmaceutical- and food-grade polymers. This structure allows for a manufacturing process that is both efficient and compliant with regulatory standards.
Focus on Rare Diseases: Epidermolysis Bullosa (EB)
Among the targeted applications is a commitment to address the specialized needs of patients with Epidermolysis Bullosa (EB), a rare genetic disorder affecting around 500,000 people globally. Many of these patients experience significant ocular complications, including persistent pain and the risk of vision-threatening scarring due to corneal abrasions. Healome's technology offers hope for effective management of these complications, as highlighted in discussions around patient stories featured in the Netflix documentary Matter of Time. Investments from organizations like DEBRA Research and Cure EB will significantly bolster Healome's efforts to innovate treatments for ocular issues arising from this rare disease.
Foundational Team with Expertise
The driving force behind Healome is a team of experienced professionals, including co-founders Professor Liam Grover, Professor Tony Metcalfe, Dr. Richard Moakes, and Dr. Richard Williams, the current CEO. This team comprises over 80 years of collective experience in biomaterials, regenerative medicine, and drug development, bolstered by multiple peer-reviewed publications originating from research conducted at the University of Birmingham's Healthcare Technologies Institute.
According to Richard Williams, CEO of Healome Therapeutics, "Using our matrix to extend the residence time of both existing and novel therapeutics unlocks the potential for fewer doses, improved adherence, and ultimately better outcomes across multiple indications. This funding allows us to advance our technology into clinical trials."
Johnathan Matlock, Co-Founder and General Partner at Empirical Ventures, expressed confidence in Healome's approach, stating, "Healome effectively targets a significant bottleneck in ocular pharmacology—the duration drugs stay on the ocular surface—using a straightforward, manufacturing-compatible technique without intricate chemical modifications. This strategy is what makes their platform potentially transformative across various therapeutic areas."
Dr. Christoph Coch, Managing Director at DEBRA Research, emphasized the broader impact of Healome’s technology for EB patients, highlighting the acute absence of effective treatments for ocular complications. The investment secured will be pivotal in driving the development of patient-centric, innovative solutions that address unmet medical needs in this space.
Conclusion and Next Steps
Healome Therapeutics is well-positioned to make significant advancements in the field of ocular therapy, and this recent funding round is a critical step toward that goal. With the aim to initiate first-in-human trials in 2027, Healome’s innovative eye-drop matrix technology promises to change the treatment landscape for ocular surface diseases profoundly.
For more information about Healome Therapeutics and its pioneering technology, visit www.healometx.com.
Company Profile
- - Founded: 2021
- - Headquarters: Birmingham, United Kingdom
- - Sector: Ophthalmology/Ocular Drug Delivery
- - Lead Investor: Empirical Ventures
- - Intellectual Property: Patents granted in various regions, with applications pending in major markets.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.